• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CytomX Therapeutics Inc. (Amendment)

    2/14/22 4:43:31 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email
    SC 13G/A 1 c020822a.htm SCHEDULE 13G (AMENDMENT NO. 2)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    CytomX Therapeutics, Inc.
    (Title of Class of Securities)
    Common Stock, $0.00001 Par Value Per Share

    (CUSIP Number)

    23284F105
    (Date of Event Which Requires Filing of this Statement)
    December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 23284F105
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,303,025 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,303,025 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,303,025 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 9.7% (see Item 4)
     
    (12) Type of reporting person (see instructions)  PN
     


    CUSIP No. 23284F105
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,303,025 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,303,025 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,303,025 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 9.7% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 23284F105
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              9,346 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       9,346 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    9,346 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 23284F105
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              6,312,371 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       6,312,371 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    6,312,371 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 9.7% (see Item 4)
     
    (12) Type of reporting person (see instructions)  IN
     



    Item 1(a) Name of issuer:
    CytomX Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.00001 per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford,
    CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware
    limited liability company. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, $0.00001 Par Value Per Share
    2(e) CUSIP Number:
    23284F105

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 6,303,025
    (b) Percent of class: 9.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,303,025 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,303,025

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 6,303,025
    (b) Percent of class: 9.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,303,025 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,303,025

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 9,346
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 9,346 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 9,346

    4. Steven A. Cohen
    (a) Amount beneficially owned: 6,312,371
    (b) Percent of class: 9.7% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 6,312,371 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 6,312,371

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by certain investment funds it manages. Point72
    Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant
    to an investment management agreement, Cubist Systematic Strategies maintains
    investment and voting power with respect to the securities held by certain investment
    funds it manages. Mr. Cohen controls each of Point72 Asset Management, Point72
    Capital Advisors Inc., and Cubist Systematic Strategies. As of December 31, 2021,
    by reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934,
    as amended, each of (i) Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Mr. Cohen may be deemed to beneficially own 6,303,025 Shares (constituting
    approximately 9.7% of the Shares outstanding) and (ii) Cubist Systematic Strategies
    and Mr. Cohen may be deemed to beneficially own 9,346 Shares (constituting <0.1%
    of the Shares outstanding). Each of Point72 Asset Management, Point72 Capital
    Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen disclaims beneficial
    ownership of any of the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than
    activities solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 14, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $CTMX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    1/20/2026$10.00Buy
    Guggenheim
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    9/17/2025$3.50Overweight
    Barclays
    7/31/2025$7.00Outperform
    Oppenheimer
    5/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytomX Therapeutics to Present at Upcoming February Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February. Guggenheim Emerging Outlook: Biotech Summit 2026Date: Wednesday, February 11, 2026Fireside Chat: 4:30 p.m. ETLocation: New York, NY World ADC London 2026Date: Wednesday, February 25, 2026Presentation: 5:00 p.m. GMTLocation: London, UK Additional information can be found on the Events and Presentations page of CytomX's website at www.cytomx.com. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharm

    2/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Announces Business Update and Company Milestones for 2026

    - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ

    1/8/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on CytomX Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $6.00

    9/22/25 8:30:10 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on CytomX Therapeutics with a new price target

    Barclays resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $3.50

    9/17/25 7:59:04 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Lester Rachael was granted 20,000 shares (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:28:36 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chu Yu-Waye was granted 75,000 shares, increasing direct ownership by 55% to 210,725 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:27:02 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Scientific Officer Belvin Marcia was granted 60,000 shares, increasing direct ownership by 22% to 332,252 units (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:25:27 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/5/26 1:20:38 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/7/25 11:13:45 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by CytomX Therapeutics Inc.

    144 - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/6/25 9:08:33 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

    3/21/24 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics Announces Business Update and Company Milestones for 2026

    - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ

    1/8/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

    - CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced third quarter 2025 financial results and provided a business update. "CytomX continued to execute against its pipeline priorities this quarter,

    11/6/25 4:10:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior t

    10/30/25 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:00:06 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 3:03:21 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care